1. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016; 103:186–194.
Article
2. Matsusaka T, Watanabe H, Enjoji M. Oat-cell carcinoma of the stomach. Fukuoka Igaku Zasshi. 1976; 67:65–73.
3. Toyokawa T, Tanaka H, Muguruma K, et al. Primary gastric small cell carcinoma: a series of seven cases. Anticancer Res. 2015; 35:563–567.
4. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017; 29:11–16.
Article
5. Oh SJ, Kim IH, Hwang YJ, et al. Two cases of neuroendocrine carcinomas of the stomach: large cell carcinoma and small cell carcinoma. Korean J Gastrointest Endosc. 2008; 37:212–217.
6. Wu QQ, Qiang WG, Wang F, et al. Management of primary gastric small cell carcinoma in China. Int J Clin Exp Med. 2015; 8:1589–1597.
7. Kim HJ, Kwon SJ, Park MH. Clinical experience of small-cell carcinomas of the stomach. J Korean Gastric Cancer Assoc. 2005; 5:252–259.
Article
8. Lee SY, Kim JI, Kim SH, et al. A case of gastric small cell carcinoma mimicking gastric lymphoma. Korean J Med. 2008; 75:694–699.
9. Terada T. Primary small cell carcinoma of the stomach: a case report with an immunohistochemical and molecular genetic analysis. Int J Clin Exp Pathol. 2013; 6:524–530.
10. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013; 24:152–160.
Article
11. Rinke A, Gress TM. Neuroendocrine cancer, therapeutic strategies in G3 cancers. Digestion. 2017; 95:109–114.
Article
12. Brenner B, Tang LH, Shia J, Klimstra DS, Kelsen DP. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol. 2007; 34:43–50.
Article
13. Casas F, Ferrer F, Farrús B, Casals J, Biete A. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer. 1997; 80:1366–1372.
14. Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010; 40:313–318.
Article
15. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68:227–232.
Article